Arrowhead Pharmaceuticals Inc. has received regulatory approval from Health Canada for REDEMPLO™ (plozasiran), a small interfering RNA (siRNA) medicine. REDEMPLO is approved as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) when standard triglyceride-lowering therapies have been inadequate. This marks the first and only siRNA medicine approved by Health Canada for FCS, and it can be self-administered at home via subcutaneous injection once every three months. The approval in Canada follows recent authorization in the United States, and REDEMPLO has been granted Breakthrough Therapy, Fast Track, and Orphan Drug Designations by the U.S. FDA, as well as Orphan Medicinal Product Designation by the European Medicines Agency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260105004282) on January 05, 2026, and is solely responsible for the information contained therein.